Eli Lilly draws the line on DTC

Eli Lilly is drawing the line on DTC—at the spots plugging the services of ambulance-chasing trial lawyers. The company surveyed 402 shrinks and found that ads by would-be litigators warning of side effects in anti-psychotics are scaring patients off the drugs.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions